Clinical Trial Update: A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001 [Phase 3]

View source ↗

Summary

Phase III trial evaluating the safety and efficacy of DWP-450 for treating glabellar lines has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Lines

Drugs mentioned

• DWP-450 (botulinum toxin type A)

Snippet

Sponsor: Evolus, Inc. | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2019-02-26